Yes! Now the prostate cancer patients with hardly weeks or months to live will be able to survive longer if they are subjected to proper immunotherapy treatment. More white patients than black patients had no PSA decline. The drugs alter the body's immune system that focuses directly on tackling cancer.
Immunotherapy is transforming the treatment of cancer and is now part of routine practice for some skin and lung cancers.
"If we can prove that in the planned new trial, it should be possible to provide some men with advanced prostate cancer with an exciting new treatment option". And one in ten were still actively benefiting from treatment. Most prostate cancers are slow growing; however, some grow very quickly.
"This is the first evidence that a subset of prostate cancer patients do spectacularly well on immunotherapy". Last month he told how he had "just had six rounds of chemo" and was expecting to undergo more.
The world's leading expert on prostate cancer Professor Johann de Bono from the Institute of cancer research said: "We hope for a revolutionary cure, but they can't call it". Some were nearly too unwell to have any treatment at all and they have been resurrected'.
Two years ago, he was given the immunotherapy drug pembrolizumab.
"One of the major challenges with immunotherapy is that we don't have many reliable tests to pick out who will benefit", added Professor Paul Workman, chief executive of The ICR. These findings show the glimmer of promise for them'.
With researchers hinting that immunotherapy works best in patients with heavily mutated cancers, there is a strong chance that the therapy will not work on all prostate cancer patients. It will then have to be assessed by the National Institute for Health and Care Excellence to see if it is cost-effective enough for prostate NHS cancer patients to receive it. "Further prospective studies in African-American patients are possible and needed to understand the impact of racial determinants on outcome of new hormonal regimens in earlier disease settings".
He says he's now planning out the next 20 years of his life, not the next two. AA plus leuprolide improved biochemical recurrence-free survival relative to leuprolide alone regardless of pretreatment PSA level, Gleason score, pathology, time to relapse from treatment, and definitive treatment type.
The tests picked up nearly 90 per cent of late-stage cancers.